Alzheimer's Disease

---

Butyrate is a gut microbial metabolite that has attracted attention in Alzheimer’s research because it appears to influence amyloid biology, neuroinflammation, and memory in preclinical models. The overall picture is promising, but the evidence is still largely from cell and animal studies rather than proven human therapy [1-3].

Why butyrate matters

Butyrate is a short-chain fatty acid produced when gut bacteria ferment dietary fiber. In the brain-disease literature, it is usually discussed in two ways: as a microbial metabolite that may shape the gut-brain axis, and as a histone deacetylase inhibitor with epigenetic effects on gene expression. That combination makes it especially interesting in Alzheimer’s disease, where inflammation, synaptic dysfunction, and impaired proteostasis all contribute to pathology [1-3].

What the studies show

Several mouse studies report that sodium butyrate improves memory performance and lowers amyloid-β burden. In an advanced-stage APPPS1-21 model, prolonged sodium butyrate treatment improved associative memory and correlated with increased hippocampal histone acetylation. In a 5xFAD model, sodium butyrate reduced brain amyloid-β levels by about 40% and improved fear-conditioning performance. A newer study in 2026 reported that butyrate reduced amyloid-β accumulation, preserved enteric neuronal connectivity, lowered inflammation, and prevented memory deficits in an Alzheimer mouse model [1-3].

How it may work

The mechanistic themes are fairly consistent across studies. Butyrate may reduce amyloid pathology, dampen neuroinflammation, preserve neuronal connectivity, and alter transcription through histone acetylation. Some of the newer work also links butyrate to the gut-brain axis, suggesting effects on gut dysfunction and enteric neurons may feed into broader brain outcomes. For a field interested in protein homeostasis, that makes butyrate notable because it may influence both upstream inflammatory tone and downstream amyloid handling.

How strong is the evidence

At present, the strongest evidence is preclinical, not clinical. The studies available through 2026 are compelling for mechanism and proof-of-concept, but they do not establish butyrate as a treatment for people with Alzheimer’s disease. A 2025 cross-sectional study also reported that higher dietary butyrate intake was associated with better cognitive function in older adults, but observational findings cannot prove causation [4].

BACK

References: 

1. Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J Alzheimers Dis. 2011;26(1):187-97. doi: 10.3233/JAD-2011-110080. PMID: 21593570.

2. Brossaud R, Oullier T, Bessard A, Aubert P, Brossard L, Mahé MM, Caillaud M, Delfino G, Paillusson S, Falentin H, Naveilhan P, Le-Loir Y, Paillé V, Neunlist M, Cissé M. The short-chain fatty acid butyrate prevents gut-brain amyloid-β pathology and neuroinflammation in an Alzheimer mouse model. Mol Psychiatry. 2026 Mar 5. doi: 10.1038/s41380-026-03522-6. Epub ahead of print. PMID: 41786890.

3. Fernando WMADB, Martins IJ, Morici M, Bharadwaj P, Rainey-Smith SR, Lim WLF, Martins RN. Sodium Butyrate Reduces Brain Amyloid-β Levels and Improves Cognitive Memory Performance in an Alzheimer's Disease Transgenic Mouse Model at an Early Disease Stage. J Alzheimers Dis. 2020;74(1):91-99. doi: 10.3233/JAD-190120. PMID: 31958090.

4. Tu J, Zhang J, Chen G. Higher dietary butyrate intake is associated with better cognitive function in older adults: evidence from a cross-sectional study. Front Aging Neurosci. 2025 Mar 28;17:1522498. doi: 10.3389/fnagi.2025.1522498. PMID: 40224959; PMCID: PMC11985818.